Aurinia Pharmaceuticals Inc (AUPH): Price and Financial Metrics
AUPH Price/Volume Stats
Current price | $5.01 | 52-week high | $12.43 |
Prev. close | $5.00 | 52-week low | $4.85 |
Day low | $4.97 | Volume | 937,384 |
Day high | $5.04 | Avg. volume | 2,405,950 |
50-day MA | $6.44 | Dividend yield | N/A |
200-day MA | $8.36 | Market Cap | 724.54M |
AUPH Stock Price Chart Interactive Chart >
AUPH POWR Grades
- Value is the dimension where AUPH ranks best; there it ranks ahead of 76.69% of US stocks.
- The strongest trend for AUPH is in Growth, which has been heading down over the past 26 weeks.
- AUPH ranks lowest in Stability; there it ranks in the 4th percentile.
AUPH Stock Summary
- With a price/sales ratio of 7.64, AURINIA PHARMACEUTICALS INC has a higher such ratio than 86.15% of stocks in our set.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.28 for AURINIA PHARMACEUTICALS INC; that's greater than it is for only 16.41% of US stocks.
- With a year-over-year growth in debt of 1,038.42%, AURINIA PHARMACEUTICALS INC's debt growth rate surpasses 99.06% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to AURINIA PHARMACEUTICALS INC are POLA, NTRB, LUCD, SWAV, and SMTI.
- Visit AUPH's SEC page to see the company's official filings. To visit the company's web site, go to www.auriniapharma.com.
AUPH Valuation Summary
- In comparison to the median Healthcare stock, AUPH's price/sales ratio is 92.86% higher, now standing at 8.1.
- Over the past 113 months, AUPH's price/earnings ratio has gone up 29.6.
Below are key valuation metrics over time for AUPH.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
AUPH | 2023-12-29 | 8.1 | 3.3 | -16.7 | -17.9 |
AUPH | 2023-12-28 | 8.4 | 3.4 | -17.2 | -18.4 |
AUPH | 2023-12-27 | 8.4 | 3.4 | -17.3 | -18.5 |
AUPH | 2023-12-26 | 8.4 | 3.4 | -17.3 | -18.5 |
AUPH | 2023-12-22 | 8.3 | 3.4 | -17.1 | -18.3 |
AUPH | 2023-12-21 | 8.4 | 3.4 | -17.2 | -18.4 |
AUPH Growth Metrics
- The 3 year net income to common stockholders growth rate now stands at -175.45%.
- Its 4 year price growth rate is now at 140.33%.
- Its year over year price growth rate is now at -8.67%.
The table below shows AUPH's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 128.999 | -115.901 | -115.456 |
2022-06-30 | 87.887 | -140.789 | -156.722 |
2022-03-31 | 66.316 | -150.897 | -168.217 |
2021-12-31 | 45.605 | -157.692 | -180.966 |
2021-09-30 | 72.231 | -126.313 | -170.2 |
2021-06-30 | 57.593 | -116.343 | -154.009 |
AUPH's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- AUPH has a Quality Grade of D, ranking ahead of 9.07% of graded US stocks.
- AUPH's asset turnover comes in at 0.178 -- ranking 206th of 682 Pharmaceutical Products stocks.
- SVRA, SESN, and VSTM are the stocks whose asset turnover ratios are most correlated with AUPH.
The table below shows AUPH's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.178 | 0.992 | -0.759 |
2021-06-30 | 0.133 | 0.994 | -0.753 |
2021-03-31 | 0.125 | 0.999 | -0.874 |
2020-12-31 | 0.131 | 1.000 | -1.010 |
2020-09-30 | 0.000 | 1.000 | -2.541 |
2020-06-30 | 0.001 | 1.000 | -10.800 |
AUPH Price Target
For more insight on analysts targets of AUPH, see our AUPH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $23.03 | Average Broker Recommendation | 1.31 (Strong Buy) |
Aurinia Pharmaceuticals Inc (AUPH) Company Bio
Aurinia Pharmaceuticals Inc., a clinical stage pharmaceutic] The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. The company was founded in 1993 and is based in Victoria, Canada.
Latest AUPH News From Around the Web
Below are the latest news stories about AURINIA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AUPH as an investment opportunity.
Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?Here is how Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have performed compared to their sector so far this year. |
Aurinia Submits IND Application to US Food & Drug Administration for AUR 200ROCKVILLE, Md. & EDMONTON, Alberta, December 20, 2023--Aurinia Submits IND Application to US Food & Drug Administration for AUR 200 |
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey MedicalAurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical are part of the Zacks Industry Outlook article. |
5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New YearInnovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio. |
This Small Pharma Could Be Targeted, But Would Be Fine Alone, TooAt the end of November, AbbVie bought ImmunoGen, Inc. for $10 billion in cash. The purchase of ImmunoGen caused that stock to soar some 90%. Back to the covered call idea on a small biopharma Aurinia Pharmaceuticals, which currently trades just under nine bucks a share. |
AUPH Price Returns
1-mo | -16.78% |
3-mo | -44.27% |
6-mo | -35.52% |
1-year | -55.55% |
3-year | -59.43% |
5-year | -22.92% |
YTD | -44.27% |
2023 | 108.10% |
2022 | -81.11% |
2021 | 65.37% |
2020 | -31.74% |
2019 | 197.07% |
Continue Researching AUPH
Here are a few links from around the web to help you further your research on Aurinia Pharmaceuticals Inc's stock as an investment opportunity:Aurinia Pharmaceuticals Inc (AUPH) Stock Price | Nasdaq
Aurinia Pharmaceuticals Inc (AUPH) Stock Quote, History and News - Yahoo Finance
Aurinia Pharmaceuticals Inc (AUPH) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...